Lawmakers urge USPTO to curb IPR denials under Fintiv

Several US lawmakers have called upon the US Patent and Trademark Office (USPTO) to curb the increase in inter partes review denials to combat the “soaring cost” of prescription drugs.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Warren calls for government to seize Pfizer patents

22 February 2022 US Senator Elizabeth Warren has urged the Department of Health and Human Services (HHS) to seize control of patents covering Pfizer’s prostate cancer drug Xtandi (enzalutamide).

Americas

Intel backs Mylan's anti-Fintiv SCOTUS stance

16 September 2021 Intel has backed Mylan's bid to convince the US Supreme Court to remove the controversial NHK-Fintiv rule, on the basis that it is “unlawful”.

Americas

Mylan, Edwards back NHK-Fintiv challenge

31 August 2021 Mylan Pharmaceutical and Edwards Lifesciences have joined a petition urging the US Supreme Court to order the US Court of Appeals for the Federal Circuit to reconsider inter partes review petitions that have been denied due to the NHK-Fintiv rule.

More on this story

Americas

Warren calls for government to seize Pfizer patents

22 February 2022 US Senator Elizabeth Warren has urged the Department of Health and Human Services (HHS) to seize control of patents covering Pfizer’s prostate cancer drug Xtandi (enzalutamide).

Americas

Intel backs Mylan's anti-Fintiv SCOTUS stance

16 September 2021 Intel has backed Mylan's bid to convince the US Supreme Court to remove the controversial NHK-Fintiv rule, on the basis that it is “unlawful”.

Americas

Mylan, Edwards back NHK-Fintiv challenge

More on this story

Americas

Warren calls for government to seize Pfizer patents

22 February 2022 US Senator Elizabeth Warren has urged the Department of Health and Human Services (HHS) to seize control of patents covering Pfizer’s prostate cancer drug Xtandi (enzalutamide).

Americas

Intel backs Mylan's anti-Fintiv SCOTUS stance

16 September 2021 Intel has backed Mylan's bid to convince the US Supreme Court to remove the controversial NHK-Fintiv rule, on the basis that it is “unlawful”.

Americas

Mylan, Edwards back NHK-Fintiv challenge